What You Should Know:
- Glytec, the only provider of cloud-based insulin management software across the continuum of care, today unveiled the latest version of its Glucommander® insulin dosing software that makes it easier for providers, nurses and pharmacists to offer best practice, personalized care.
- These innovations help streamline workflows, improve patient outcomes and offer tighter support for the industry’s top electronic health record (EHR) systems. They also closely follow the next evolution of GlucoMetrics®, which Glytec unveiled this spring to provide new insights and analytics that help hospitals improve glycemic management and readiness for impending CMS measures related to hypoglycemia and hyperglycemia.
Improving Personalized Medicine to Increase Patient Compliance
More than 300 hospitals nationwide trust Glytec’s eGlycemic Management System® (eGMS®) to ensure safe and effective glycemic management for their patients. The company’s eGMS centers on Glucommander – the only cloud-based, FDA-cleared software designed to provide personalized IV and SubQ insulin dosing for patients living with and without diabetes. Developed through extensive feedback and close collaboration with customers, Glucommander 3.5.3.0 software is easier to use and more intuitive to help health systems prioritize and improve patient safety.
“Glytec is leading the way to a future where every hospital across the country provides the highest quality glycemic care possible,” said Jordan Messler, MD, Chief Medical Officer at Glytec. “We are working towards making that vision a reality by establishing Glucommander as the standard of care for insulin dosing through innovation, continuous improvement, collaboration and clinical excellence. Since our inception, we have worked closely with customers and partners to understand workflows in busy hospitals and ensure our tools fit seamlessly to enhance operations and support improved patient outcomes. Today’s release is an important milestone in our journey and paves the way for even greater things to come.”
With the new updates, Glytec strengths its commitment to innovation and drives faster time to value for:
● Providers with enhanced order flexibility. Aligning the orders integration more closely with clinical best practice means ordering is easier, reducing the learning curve for new providers and decreasing the risk of a patient starting with the wrong parameters.
● Nurses with improved IV and SubQ transition workflows. Front-line nurses will have easier, at-a-glance access to information needed for a safer transition of patients from IV to SubQ insulin.
● Pharmacists with the availability of D10W. Hospital pharmacists have expanded medication options available to them to treat hypoglycemia in the rare instances when it
occurs and the ability to be nimble in face of D50W shortages. Glytec is also updating its oral carbohydrate recommendations for treating cases of severe hypoglycemia from 15 grams to 30 grams, based on the results of its recent research.
